Coloma Jason V sold $160K of MAZE (indirect holdings)
Coloma Jason V (Chief Executive Officer) sold 6,090 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at $26.20 ($0.16M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may monitor for patterns in insider activity, but a single 10b5-1 sale typically carries limited incremental information.
Market read
Insider selling disclosed at $26.1965/share; likely sentiment noise rather than a fundamental driver.
What to watch
The filing does not indicate whether other insiders bought/sold around the same period or whether there were concurrent operational catalysts.
Background
SEC Form 4 discloses insider transactions; this one is an open-market sale by the CEO with a pre-arranged Rule 10b5-1 plan.
Ticker impact
Maze Therapeutics CEO sold 6,090 shares in an open-market transaction for about $159.5K, disclosed via Form 4.
Low near-term impact; any reaction is likely muted given the pre-arranged 10b5-1 structure.
Form 4 insider sales can move microstructure sentiment, but the article specifies a pre-arranged 10b5-1 plan, reducing signal about near-term company outlook.
Market effects
No clear sector read-through; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can reflect routine liquidity needs rather than bearish expectations, so price impact may be overstated.
Key entities
- issuerMaze Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderColoma Jason V
CEO and director who sold 6,090 shares.